Abstract 19162: A Novel Hydrogen Sulfide Prodrug, SG-1002, Augments Angiogenesis in a Swine Model of Critical Limb Ischemia

Introduction: Despite advances in revascularization, treatments for critical limb ischemia (CLI) have been largely unsuccessful. Hydrogen sulfide (H2S), a gaseous signaling molecule, exerts potent vasodilatory and proangiogenic effects. We sought to determine whether a novel H2S prodrug, SG-1002, promotes peripheral revascularization. Methods: CLI was generated in Yucatan miniswine (n=17) by placement of an Amplatzer vascular plug deployed within a Viabahn stent in the proximal external iliac artery. At day 7 post-CLI pigs received daily placebo or SG-1002 (1600 mg PO). Blood flow was measured weekly by ankle/brachial index (ABI) cuff-pressures. Plasma levels of H2S, the H2S metabolite sulfane sulfur (SS), and the NO metabolite, nitrite were measured. At day 42 post-CLI, quantitative digital subtraction angiography (DSA) vasculature was performed and number of opacified vessels counted. Results: ABI measurements revealed a reduction to 0 following the CLI procedure. ABI improved but continued to demonstra...